Citations

Clear

4847 citation(s) found for "Tu, Eric".

Imaging of Bone Surface Lesions
Parwal, Utkarsh , Khoo, Allison , Rhodes, Nicholas G. , McEnulty, Patrick G. , Baker, Jonathan C. , Northrup, Benjamin E. , Velde, Theodore L. Vander , Malik, Mariam A., Jennings, Jack W. , Napier, Kelby B. , Pang, Eric V, Baker, Jonathan C , Northrup, Benjamin E , Vander Velde, Theodore L , Jennings, Jack W , Napier, Kelby B , Pang, Eric V.

Mayo Clinic

RadioGraphics | November 6, 2025 | Volume: 45 | Issue: 12 | Pages: No page available

10.1148/rg.240012 | PMID 41196715 Get It

Bone surface lesions include a variety of benign and malignant tumors and nonneoplastic entities, and knowledge of the different cell types and cortical bone surface anatomy equips radiologists to provide a useful differential diagnosis for these lesions.
Shape analysis of the amygdala, hippocampus and thalamus in former American football players
John, Omar , Wickham, Alana, Jung, Leonard , Mirmajlesi, Anya S, Stearns, J. W. , Breedlove, Katherine M. , Billah, Tashrif , Pasternak, Ofer , Chamaria, Arushi , Bernick, Charles , Balcer, Laura J. , Rushmore, R. Jarrett , Alosco, Michael L. , Lin, Alexander , Cummings, Jeffrey L., Reiman, Eric M. , Arciniega, Hector , Su, Yi, Chen, Kewei, Protas, Hillary, Boker, Connie, Alosco, Michael L, Au, Rhoda, Cantu, Robert C, Farrer, Lindsay, Helm, Robert, Katz, Douglas I, Kowall, Neil, Mez, Jesse, Mercier, Gustavo, Otis, James, Weller, Jason, Simkin, Irene, Andino, Alondra, Conneely, Shannon, Diamond, Courtney, Fagle, Tessa, Haller, Olivia, Hunt, Tennyson, Gullotti, Nicole, Mariani, Megan, Mayville, Brian, McLaughlin, Kathleen , Nanna, Mary, Platt, Taylor, Rice, Fiona, Sestak, Madison, Annis, Douglas S. , Dixon, Diane, Finney, Carolyn, Gallagher, Kerrin, Hartlage, Kaitlin , Martin, Brett, Palmisano, Joseph , Pine, Brittany, Fitzsimmons, Jennifer, Pasternak, Ofer, Arcinieago, Hector, Coello, Eduardo , Coleman, Michael J. , Jung, Leonhard, Liao, Huijun, Loy, Maria, Rizzoni, Elizabeth, Schultz, Vivian , Silva, Annelise, Vessey, Brynn, Banks, Sarah J. , Ritter, Aaron, Cruz, Raelynn de la, Durant, Jan, Golceker, Morgan, Harmon, Nicolette, Kaylegian, Kaeson, Long, Rachelle, Nance, Christin, Sandoval, Priscilla, Serrano, Andrew, Falk, Bryce W., Duffy, Amy, Howard, Marci, Montague, Michelle , Osgood, Thomas, Babcock, Debra, Marmar, Charles R. , Hasanaj, Lisena, Serrano, Liliana , Al-Kharafi, Alhassan, George, Allan , Martin, Sammie, Runge, William, Peskind, Elaine R. , Colasurdo, Elizabeth A. , Marcus, Daniel S., Gurney, Jenny , Greenwald, Richard M., Johnson, Keith A, Jung, Leonard B , Stearns, Jared , Breedlove, Katherine , Tripodis, Yorghos , Adler, C H , Alosco, Michael L , Koerte, Inga K , Arciniega, Hector , Kim, Nicholas , Daneshvar, Daniel H. , Coleman, Michael , Tripodis, Yorghos , Adler, Charles H. , Stern, Robert A. , Shenton, Martha E. , Bouix, Sylvain , Su, Yi, Chen, Kewei, Alosco, Michael L., Au, Rhoda, Cantu, Robert C. , Mez, Jesse, Weller, Jason , Simkin, Irene, Fagle, Tessa, Pulukuri, Surya Vamsi , McClean, Michael D , Annis, Douglas, Chaisson, Christine E. , Finney, Carolyn, Lü, Jun , Ojo, Emmanuel, Ramachandran, Janani , Bonke, Elena M. , Wiegand, Tim L. T. , Miller, Jason Rafe , Sabbagh, Marwan Noel , II, Robert W. Turner , Marek, Kenneth , Dodick, David W. , Geda, Yonas E. , Wethe, Jennifer V. , Falk, Bryce, Montague, Michelle, Bellgowan, Patrick S.F. , Barr, William , Goldberg, Judith D. , Wısnıewskı, Thomas , Kirov, Ivan I. , Lui, Yvonne W. , George, Allan, Riley, Edward P. , Cummings, Jeffrey L. , Johnson, Keith A.

Mayo Clinic

Brain Communications | November 6, 2025 | Volume: 7 | Issue: 6 | Pages: No page available

10.1093/braincomms/fcaf440 | PMID 41277896 Get It

Abstract Repetitive head impacts are common in contact and collision sports and are linked to structural brain changes and an elevated risk of neurodegenerative diseases such as Chronic Traumatic Encephalopathy. Identifying early in vivo structural markers remains challenging. Although diagnosis currently requires post-mortem confirmation, clinical symptoms, including cognitive impairment and behavioural changes, are reflected in the diagnosis of Traumatic Encephalopathy Syndrome. These symptoms align with dysfunction in key brain regions—amygdala, hippocampus and thalamus—which support memory, emotion and behaviour and commonly show tau pathology in Chronic Traumatic Encephalopathy. This study uses shape analysis to examine structural differences in these regions between former American football players and unexposed asymptomatic controls and evaluates the influence of age, head impact exposure and clinical diagnosis on brain structure. We analyzed brain morphology in former American football players (n = 163) and unexposed, asymptomatic controls (n = 53). Structural segmentation was performed with FreeSurfer 7.1, and the shape analysis pipeline was used to generate subregional reconstructions. Vertex-level morphometry, based on the logarithm of the Jacobian determinant and radial distance, quantified local surface area dilation and thickness. Group differences were examined with covariate-adjusted linear regression models contrasting football players and controls, as well as participants with and without a Traumatic Encephalopathy Syndrome diagnosis. Partial correlations examined the influence of age, age of first football exposure and cumulative head impact index metrics, including frequency, linear acceleration and rotational force. Models were adjusted accordingly for age, body mass index, education, race, imaging site, apolipoprotein ϵ4 status and total intracranial volume. Former football players exhibited bilateral surface area contractions in the hippocampus and amygdala, along with reduced amygdala thickness, compared to controls. Older age was associated with widespread surface contractions and thinning across all regions, except for preserved thickness in the left hippocampus. An earlier age of first exposure to football correlated with surface contractions in the thalamus and left hippocampus. Greater cumulative linear acceleration was linked to bilateral hippocampal surface contractions and reduced thickness in the left thalamus, while greater rotational force exposure was associated with hippocampal thinning. No significant structural differences were found between players with and without a diagnosis of Traumatic Encephalopathy Syndrome. These findings extend volume-based research by revealing localized alterations in surface area dilation and thickness and emphasize the roles of age and repetitive head impact exposure in long-term brain changes.
Characterization of Maternal and Fetal Immunity Following in Utero Spina Bifida Repair and Surgery‐Induced Preterm Birth
Carmona, K Martinez , Lothert, Petra K., Fedyshyn, Bohdana , Jang, Jin Sung , Govindan, Aparna, Portella, Percy N. Pacora, Lemens, Maureen A. , Chakraborty, Rana, Schenone, Mauro , Enninga, Elizabeth Ann L. , Martinez Carmona, Katherine , Schenone, Mauro H , Enninga, Elizabeth Ann L , Portella, Percy Pacora , Ruano, Rodrigo , Peiro, Jose Luis , Bergh, Eric P.

Mayo Clinic

Prenatal Diagnosis | November 6, 2025 | Volume: 45 | Issue: 13 | Pages: 1816-1826

10.1002/pd.70021 | PMID 41192922 Get It

ABSTRACT Objective Fetal surgery (FS) for spina bifida (SB) repair improves infant outcomes; however, spontaneous preterm birth (sPTB) is common. We aimed to evaluate maternal and fetal immune responses following FS for SB repair. Method Pregnant participants undergoing fetoscopic SB repair at 24–26 weeks of gestational age (GA) were prospectively recruited and compared to GA matched low‐risk controls. Blood samples were collected at baseline, 2‐week post‐surgery (POD14), and delivery. Cytokine analysis, flow cytometry, and T cell receptor (TCR) sequencing were performed. Results sPTB occurred in 5/6 of the FS group (0/6 of controls). Maternal blood in the FS group demonstrated increased alpha‐fetoprotein (AFP) and anti‐inflammatory IL‐1RA at baseline and POD14, increased pro‐inflammatory IL‐8 only post‐operatively, and elevated growth factors throughout. T cell phenotypes following FS revealed reduced TH17 frequency but increased activation receptors on cytotoxic T cells. At delivery, the FS cohort had reduced Th2 and Th17 helper T cells and CD4+ memory T cells, but CD8 T cells still showed increased activation. No TCR expansion was detected post‐surgery, suggesting antigen‐independent activation. Cord blood in FS repaired neonates had increased AFP, IL‐8, IL‐1RA. Conclusion Systemic immune changes following FS, particularly T cell maturation and activation, were observed. Further characterization of these mechanisms may help predict and prevent surgery‐induced PTB, improving outcomes.
Semaglutide and diabetic retinopathy: an OHDSI network study
Cai, Cindy X. , Hribar, Michelle R. , Wang, Sophia Y. , Swaminathan, Swarup S. , Flowers, Alexis , Brown, Eric N. , Chen, John J. , Chen, Aiyin , Alshammari, Thamir , Falconer, Thomas , Martin, Benjamin , Westlund, Erik , Mathioudakis, Nestoras , Fan, Ruochong, Stocking, Jacqueline C. , Humes, Izabelle, McCoy, David , Adibuzzaman, Mohammad, Areaux, Raymond G. , Brash, James T., Morgan‐Cooper, Hannah, Desai, Priya , Rustam, Zainab, Zhu, Gu , Swerdel, Joel N. , Suchard, Marc A. , Ryan, Patrick , Cai, Cindy Xinji , Barkmeier, Andrew, Stocking, Jacqueline C , Chen, John J , Mathioudakis, Nestoras N , Nishimura, Akihiko, Baxter, Sally L. , Goetz, Kerry , Toy, Brian C. , Barkmeier, Andrew J. , Xu, Benjamin Yixing , Leng, Theodore , Boland, Michael V. , Bu, Fan , Martin, Benjamin, Zhang, Linying , Fan, Ruochong, Wilcox, Adam B , Lai, Albert M. , Xie, Yangyiran , Lee, Lok Hin , Dorr, David A , Weiskopf, Nicole G. , Desai, Priya, Tran, Diep D. , Rustam, Zainab, Sena, Anthony G. , Nagy, Paul G. , Schuemie, Martijn J. , Hripcsak, George

Mayo Clinic

BMJ Open Diabetes Research & Care | November 5, 2025 | Volume: 13 | Issue: 6 | Pages: e005424

10.1136/bmjdrc-2025-005424 | PMID 41192935 Get It

Introduction Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes mellitus (T2D), has potential associations with higher rates of diabetic retinopathy (DR) complications including proliferative DR (PDR) and diabetic macular edema (DME). The purpose of this study was to determine whether an association exists between semaglutide and PDR and treatment-requiring DR/DME. Research design and methods This was a retrospective cohort study of 14 databases (six administrative claims and eight electronic health records) in the Observational Health Data Sciences and Informatics Evidence Network. Adults with T2D on semaglutide, other GLP-1RA (dulaglutide, exenatide), or non-GLP-1RA medications (empagliflozin, sitagliptin, glipizide) from 1 December 2017 to 31 December 2023 were included. The association between semaglutide and PDR or treatment-requiring DR/DME was assessed using an active-comparator cohort design comparing new users of semaglutide as second-line T2D treatment to those on other GLP-1RAs and non-GLP-1RAs. Propensity score-adjusted Cox proportional hazards models were used to estimate hazard ratios (HRs). Network-wide HR estimates were generated using a random-effects meta-analysis. Results The study included 810 390 new semaglutide users for T2D. PDR risk for semaglutide was similar to dulaglutide (HR 0.81, 95% CI 0.42 to 1.54, p=0.51), empagliflozin (HR 0.83, 95% CI 0.53 to 1.30, p=0.41) and sitagliptin (HR 0.83, 95% CI 0.45 to 1.55, p=0.57) but was lower than glipizide (HR 0.59, 95% CI 0.39 to 0.88, p=0.01). The risk for treatment-requiring DR/DME for semaglutide was similar to empagliflozin (HR 0.66, 95% CI 0.43 to 1.02, p=0.06) but lower than dulaglutide (HR 0.53, 95% CI 0.31 to 0.91, p=0.02), sitagliptin (HR 0.46, 95% CI 0.26 to 0.81, p=0.008) and glipizide (HR 0.55, 95% CI 0.33 to 0.91, p=0.02). Conclusions and relevance We did not identify increased risk for either PDR or treatment-requiring DR/DME comparing semaglutide with other GLP-1RAs or non-GLP-1RAs. Patients with T2D should still undergo close eye care follow-up, particularly when initiating new antihyperglycemic medications.
603 SUPRAME: a phase 3 trial evaluating IMA203 PRAME-directed TCR T-cell therapy vs investigator’s choice in previously treated advanced cutaneous melanoma
Moser, Justin, Amaria, Rodabe N, Warner, Allison Betof, Chmielowski, Bartosz, Fecher, Leslie A, Chandrasekaran, Sanjay, Chen, Ruqin, Cowey, Charles L, Daniels, Gregory A, Daud, Adil, Dimitrova, Maya, Dudek, Arkadiusz Z, Haugh, Alexandra, Hernandez-Aya, Leonel, Hu-Lieskovan, Siwen, Hurwitz, Michael E, Isaacs, James M, Karapetyan, Lilit, Lee, Sylvia, Mammen, Joshua MV, Mckean, Meredith, Mitchell, Tara C, Moschos, Stergios J, Naqash, Abdul Rafeh, Olson, Daniel J, Olszanski, Anthony J, Patel, Sapna P, Poklepovic, Andrew S, Robert, Caroline, Schadendorf, Dirk, Seedor, Rino S, Seetharam, Mahesh, Smithy, James W, Solomon, Benjamin M, Taylor, Matthew H, Terhune, Julia H, Viray, Hollis A, Whitman, Eric D, Wu, Richard, Xing, Yan, Krishna, Delfi, Mayer-Mokler, Andrea, Pankov, Dmitry, Britten, Cedrik M, Luke, Jason J, Moser, Justin, Amaria, Rodabe N, Warner, Allison Betof, Chmielowski, Bartosz, Fecher, Leslie A, Chandrasekaran, Sanjay, Chen, Ruqin, Cowey, Charles L, Daniels, Gregory A, Daud, Adil, Dimitrova, Maya, Dudek, Arkadiusz Z, Haugh, Alexandra, Hernandez-Aya, Leonel, Hu-Lieskovan, Siwen, Hurwitz, Michael E, Isaacs, James M, Karapetyan, Lilit, Lee, Sylvia, Mammen, Joshua MV, Mckean, Meredith, Mitchell, Tara C, Moschos, Stergios J, Naqash, Abdul Rafeh, Olson, Daniel J, Olszanski, Anthony J, Patel, Sapna P, Poklepovic, Andrew S, Robert, Caroline , Schadendorf, Dirk, Seedor, Rino S, Seetharam, Mahesh, Smithy, James W, Solomon, Benjamin M, Taylor, Matthew H, Terhune, Julia H, Viray, Hollis A, Whitman, Eric D, Wu, Richard, Xing, Yan, Krishna, Delfi, Mayer-Mokler, Andrea, Pankov, Dmitry, Britten, Cedrik M, Luke, Jason J

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: A687-A687

10.1136/jitc-2025-sitc2025.0603 Get It

Abstract 4366927: Cost Effectiveness of Intravascular Use for Lower Extremity Deep Venous Procedures in Real World Practice
Herzig, Matthew , Kim, Joseph , Sabri, Saher S. , Patel, Parag, Li, Siling , Desai, Kush , Song, Yang , Secemsky, Eric A.

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4366927 Get It

Introduction: The use of intravascular ultrasound (IVUS) to guide lower extremity deep venous stent placement is associated with improved identification of the degree of maximal vessel stenosis, vessel obstruction, and thrombus burden, compared to venography alone. As the US medical system moves towards value-based care, the financial impact of interventional tools requires close consideration. Currently, there are limited evaluations of the cost effectiveness of IVUS during venous procedures. Research Question: This study seeks to examine the cost-effectiveness of IVUS in lower extremity deep venous interventions. Methods: Medicare fee-for-service claims data from 2016 through 2021 for beneficiaries aged ≥ 65 years undergoing lower extremity venous interventions with stent placement, thrombolysis, and/or thrombectomy were analyzed. Cost ratios between IVUS-guided and non-IVUS-guided procedures were assessed using gamma regression, adjusting for demographic and clinical variables. Results: A total of 52,610 patients were included, with 42.6% undergoing IVUS-guided procedures. IVUS utilization varied by setting, with higher usage in hospital-based outpatient centers (75.3%) and ambulatory surgical centers/outpatient-based laboratories (ASC/OBL; 86.4%) compared to inpatient hospitalizations (10.4%). Among inpatient procedures, IVUS-guided venous intervention was associated with greater cost than non-IVUS procedures at 90 days, with an adjusted cost ratio of 1.04 (95% CI 1.01-1.07), yet was associated with an average 0.6-day shorter hospitalization (p < 0.001; Figure 1, Figure 2 ). There were marginal increased costs associated with use of IVUS in inpatient procedures persisting through one- and three-years follow-up, with adjusted cost ratios of 1.05 (95% CI 1.02-1.08) and 1.05 (95% CI 1.02-1.09), respectively. In contrast, IVUS use was associated with significant cost savings in outpatient settings, with adjusted cost ratios of 0.71 (95% CI 0.69-0.73) in hospital-based outpatient settings and 0.75 (95% CI 0.73-0.78) in ASC/OBL at 90 days. These cost savings persisted at one- and three-year follow-up. Conclusions: IVUS-guided venous intervention was associated with cost savings in outpatient and ASC/OBL settings, while maintaining near cost equivalence in inpatient settings. These findings suggest that in addition to the clinical benefit of IVUS for venous intervention, IVUS is a cost-effective strategy, particularly in the outpatient setting.
Abstract 4358519: Combination Therapy with SGLT2 Inhibitors and Tafamidis Improves Outcomes More Than Tafamidis Alone in ATTR Cardiac Amyloidosis
Ali, Nima Baba , Esfahani, Sogol Attaripour , Abdelfattah, Fatmaelzahraa , Bismee, Nadera N. , Sheashaa, Hesham, Ibrahim, Omar , Razaghi, Mahshad , Rosenthal, Julie , Steidley, D. Eric , Arsanjani, Reza, Abbas, Mohammed Tiseer , Awad, Kamal , Pereyra, Milagros , Scalia, Isabel G. , Farina, Juan M. , Arsanjani, Reza

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4358519 Get It

Background: Among cardiac amyloidosis subtypes, transthyretin cardiac amyloidosis (ATTR) has gained increased recognition with the development of disease-specific therapies. Tafamidis, a selective oral stabilizer of the transthyretin tetramer, has emerged as an effective treatment. In the broader heart failure landscape, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have become cornerstone therapies across the ejection fraction spectrum, improving survival and reducing hospitalizations in both HFrEF and HFpEF. However, the clinical benefit of combining Tafamidis with SGLT2i in ATTR remains largely unknown. Hypothesis: Combination therapy with Tafamidis and SGLT2i provides added clinical benefits in patients with ATTR cardiac amyloidosis. Methods: This retrospective cohort study included adults with confirmed ATTR cardiac amyloidosis diagnosed via 99mTc-pyrophosphate scintigraphy and treated with Tafamidis alone or with an SGLT2i across three academic centers from January 2019 to February 2025. Baseline characteristics and outcomes were collected from medical records. The primary endpoint was all-cause mortality. Kaplan-Meier analysis and multivariable Cox proportional hazards modeling were used, adjusting for age, sex, atrial fibrillation, diabetes, hypertension, hyperlipidemia, ejection fraction (EF), and glomerular filtration rate (GFR). Results: Among the 1,211 patients included in the 3-year follow-up analysis,946 received Tafamidis monotherapy and 265 received a combination of Tafamidis and an SGLT2i. The mean age of the cohort was 71.9 years (SD ±9.4), and 87.3% were male. A total of 142 mortality events occurred, with a higher cumulative mortality rate observed in the tafamidis-only group (16.3%) compared to the combination group (9.4%) (log-rank p = 0.042). In the multivariable Cox proportional hazards model, combination therapy with Tafamidis and an SGLT2i was independently associated with a significantly lower risk of mortality (adjusted HR =0.576, 95% CI:0.334–0.992, p =0.04). Additionally, increasing age (HR =1.049, 95% CI:1.024–1.074, p < 0.001) was associated with higher mortality, while EF(HR =0.971, 95% CI:0.958–0.984, p< 0.001) and GFR (HR =0.975, 95% CI:0.965-0.985, p< 0.001) were with lower mortality. Conclusion: Combination therapy with Tafamidis and SGLT2i was associated with improved survival compared to Tafamidis alone in ATTR cardiac amyloidosis. Further prospective trials are needed to validate these findings and guide therapy optimization.
Abstract 4369639: Pulmonary congestion assessment by automated quantitative computer tomography in heart failure patients
Jenča, Dominik , Yarnykh, Svetlana , Hiti, Hikmet Al, Bínová, Jana, Peterson, S. , Newell, John D. , Melenovský, Vojtěch , Adla, Theodor , Hoffman, Eric A. , Borlaug, Barry A.

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4369639 Get It

Introduction: Heart failure (HF) affects interstitial lung structure and function. AI-assisted quantitative computed tomography (qCT) offers possibility of objective assesment of lung structure, allowing to detect the presence and the severity of HF. Hypothesis: Can automated qCT analysis discriminate HF from controls and identify tissue structures most linked to degree of congestion ? Methods: Subjects underwent right heart catheterization (RHC), native CT chest imaging (full inspiration/expiration) by Naeotom-α photon-counting CT scanner (Siemens), lab testing, echocardiography. Automated AI-based analysis (VIDA Diagnostics) was employed to evaluate lung volumes, densities and tissue texture. Image series were used in mediastinal and lung window reconstruction with slice thickness 0,8 mm and increments 0,5 mm. Results: 186 HF patients (85% HFrEF, NYHA 2.8±0.5, 58 y, 80% males, NTproBNP 4491 pg/ml, LVEF 26%) and 43 controls of similar sex and BMI were analyzed; both groups free of primary lung disease. In HF, 85 % had PH (mPAP>20mmHg). HF patients had comparable inspiratory lung volume, reduced air volume and increased lung tissue volume, compared to controls. Mean lung density (-782±50 vs -832±25 HU, p<0.0001), density variability and estimated lung fluid content (21.3 vs 16.7%, p<0.0001) were all higher in HF compared to controls. Across various density cut-offs, the most notable difference was at lung tissue density < -856 HU at inspiration. Lung tissue density corelated with mean PA pressure (r=0.49, p<0.0001), and less with pulmonary vascular resistance (r=0.21, p=0.006). Insp/exp scan analysis showed no difference in air trapping, but reduced lung tissue compliance (Jacobian strain: 1.8±0.4 vs 1.6±0.3, p=0.0005) in HF. Lung texture analysis showed increased ground-glass opacity (GGO) mass (48.8 g vs 9.1 g; p < 0.001), reticulation (42.2 g vs. 8.4 g; p < 0.001) and consolidation (0.5 g vs 0.2 g; p=0.0011) in HF compared to controls, with no difference in honeycombing. GGO mass correlated strongly with pulmonary capillary wedge pressure (PCWP) (r=0.48, p<0.001) and mitral regurgitation grade (r=0.28,<0.0001), but not with inflammation (hsCRP, IL6, WBC), smoking exposure or oncotic pressure. Conclusions: qCT distinguished HF patients from controls by increased lung tissue mass, reduced air volume, increased lung density and increased mass of GGO and reticulation. GGO mass in HF strongly reflects increased hydrostatic pressure, but not inflammation.
Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Du
Shi, Qian , Collisson, Eric A. , Dixon, Jesse G. , Cusnir, Mike , Winograd, Rafael , Botta, Gregory P. , Shergill, Ardaman , Ko, Andrew , Tsang, Erica S , Shi, Qian , Olive, Kenneth P , Collisson, Eric , Dixon, Jesse G , Cusnir, Mike , Winograd, Rafael , Botta, Gregory P , Shergill, Ardaman , Meyerhardt, Jeffrey A , O'Reilly, Eileen M , Ko, Andrew H , Wadlow, Raymond Couric , Meyerhardt, Jeffrey A. , O’Reilly, Eileen M.

Mayo Clinic

JCO Oncology Advances | October 31, 2025 | Volume: No volume available | Issue: 2 | Pages: No page available

10.1200/oa-25-00099 | PMID 42610096 Get It